Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Jurcic, J. G.; Levy, M. Y.; Park, J. H.; Ravandi, F.; Perl, A. E.; Pagel, J. M.; Smith, B. D.; Estey, E. H.; Kantarjian, H.; Cicic, D.; Scheinberg, D. A. |
| Abstract Title: | Phase I trial of targeted alpha-particle therapy with Actinium-225 ((225)Ac)-lintuzumab and low-dose cytarabine (LDAC) in patients age 60 or older with untreated acute myeloid leukemia (AML) |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394452305129 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.4050.4050 |
| Notes: | Meeting Abstract: 4050 -- Source: Wos |
